For Autocrats, and Others, Coronavirus Is a Chance to Grab Even More Power “As the coronavirus pandemic brings the world to a juddering halt and anxious citizens demand action, leaders across the globe are invoking executive powers and seizing virtually dictatorial authority with scant resistance. As the new laws broaden…
David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify the risk of liver damage from Pfizer’s diabetes drug Rezulin — which eventually was withdrawn from the market….
Part III. The Untouchable Third Rail in Healthcare—The Vaccine Controversy: Core Issues
Part II. What Do We Get for All That Money? A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic; Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;
The decision to suspend the trial is viewed as highly questionable, raising disturbing questions about the role that marketing played–especially in light of the fact that Zytiga’s patent is due to expire in 2017.
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best).
The single National Biodefense Science Board panelist who voted against the recommendation in support of an anthrax vaccine test in children was Patricia Quinlisk, M.D., M.P.H. State Epidemiologist and Medical Director Iowa Department of Public Health, who chaired the NBSB panel.
Five weeks after publishing a grossly dis-informative front-page report by Gina Kolata about Alzheimer’s research,The New York Times published a lengthy three paragraph correction.
Dr. Charles Schulz is scheduled to present "How to help parents of a first psychotic episode patient," at Annual APA Meeting –it is closed to public. What is it that psychiatrists and the APA do not want parents or the public to know?
Forbes Magazine reports "How one company turned a rejection into a thumbs up, and what it could mean for the drug industry as a whole."
A document filed in Federal District Court, Orlando Fla, by plaintiffs "in response to AstraZeneca’s motion to exclude evidence and argument about Dr. Macfadden’s personal relationships," sheds light on yet another facet of manipulation–sexual exploitation.
